Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Amgen's former stock buyback program on borrowed money fails

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Mar 17, 2023 1:05pm

322 Views

Post# 35345393

Amgen's former stock buyback program on borrowed money fails

... and is coming home to roost as rising interest rates and unreported tax obligations (US$10 Bln) take hold of this company, due to corporate mismangement and a former stock buy-back program using borrowed money when money was cheap. Now Amgen is trying to spin its mismanagement by blaming inflation and drug pricing pressure for the company's troubles.

https://www.fiercepharma.com/pharma/amgen-cuts-450-workers-cites-drug-pricing-pressure-and-inflation

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing